A Phase 3 interventional study of Suvorexant and Placebo in Insomnia, sponsored by Merck Sharp & Dohme LLC. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders — 5 open to participants now, 5 under way, 1 of them phase 3. suvorexant · Sleep Initiation and Maintenance Disorders.
Among the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 3, and was the 34th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →5 of the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–75
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance · Sites in United States
Ages 21–65
University of Minnesota · Sites in United States
Ages 65+ · Healthy volunteers
Northern California Institute of Research and Education · Sites in United States
Ages 18–75
By country, each count listing its studies:
suvorexant: first FDA approval 2014 (BELSOMRA). What it is approved for, and how studies give it, is on its page →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 300 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 44 across the 38 interventional studies. Of the 30 that completed or were terminated, 24 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
20 studies in Sleep Initiation and Maintenance Disorders by Merck & Co., Inc: 1 open now, 1 under way, 1 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 20 studies in Sleep Initiation and Maintenance Disorders by Merck & Co., Inc, this one is the 10th largest by planned enrollment, is the only one that started in 2025, is one of 11 in phase 3, and was the 20th registered.
Merck & Co., Inc’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2006.
2 of the studies testing suvorexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06655883Phase 3Merck Sharp & Dohme LLCA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | 2027-06-24 |
| NCT06679062Pharmacotherapies for Alcohol and Substance Use Disorders AllianceSuvorexant for Treatment of AUD and PTSD | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Among Merck & Co., Inc’s 20 in Sleep Initiation and Maintenance Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 10 mg of suvorexant for the first three nights, increased to 20 mg of suvorexant nightly thereafter at the investigator's discretion, for up to approximately 8 weeks.
Drug: Suvorexant
Participants receive suvorexant-matching placebo for up to approximately 8 weeks.
Drug: Placebo
Oral Tablet
Also known as: MK-4305
Oral Tablet
Change from Baseline in Total Sleep Time at Week 8
Total sleep time will be measured in a sleep laboratory by polysomnography at the participant's habitual bedtime. Change from baseline in total sleep time at Week 8 will be reported.
Time frame: Baseline and Week 8
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 10 weeks
Number of Participants Who Experience One or More Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that at any dose results in death, is life threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is another important medical event deemed such by medical or scientific judgement.
Time frame: Up to approximately 10 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 8 weeks
Change from Baseline in Wakefulness after Persistent Sleep Onset at Week 8
Wakefulness after persistent sleep onset will be measured in a sleep laboratory by polysomnography at the participant's habitual bedtime. Change from baseline in wakefulness after persistent sleep onset at Week 8 will be reported.
Time frame: Baseline and Week 8
Number of Participants Who are Positive for Substance Abuse at Day 1
A positive assessment for substance abuse at Day 1 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.
Time frame: Day 1
Number of Participants Who are Positive for Substance Abuse at Day 4
A positive assessment for substance abuse at Day 4 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.
Time frame: Day 4
Number of Participants Who are Positive for Substance Abuse at Week 2
A positive assessment for substance abuse at Week 2 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.
Time frame: Week 2
Number of Participants Who are Positive for Substance Abuse at Week 4
A positive assessment for substance abuse at Week 4 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.
Time frame: Week 4
Number of Participants Who are Positive for Substance Abuse at Week 8
A positive assessment for substance abuse at Week 8 is defined as either a positive urine drug test for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis OR a positive response on the Substance Use History (SUH) Since Last Assessment questionnaire. The Substance Use History Questionnaire (SUH) has been developed specifically for this study. This is a self-reported questionnaire used to obtain a variety of quantitative estimates of cannabis, alcohol, and other nonmedical substance use. The SUH Since Last Assessment Questionnaire will be used to assess nonmedical substance and alcohol use since the previous study visit.
Time frame: Week 8
Number of Participants with Positive Urine Drug Screen
A positive urine drug screen is defined as urine drug test positive for opioids and other nonmedical substances including fentanyl, cocaine, amphetamines, benzodiazepines, and cannabis
Time frame: Day 1, Day 4, Week 2, Week 4, Week 8
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.
Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 20 months is above that.
Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suvorexant
Sleep Initiation and Maintenance Disorders →